当前位置: X-MOL 学术Chem. Sci. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
A fluorescent ESIPT-based benzimidazole platform for the ratiometric two-photon imaging of ONOO−in vitro and ex vivo
Chemical Science ( IF 7.6 ) Pub Date : 2020-06-16 , DOI: 10.1039/d0sc02347g
Maria L Odyniec 1 , Sang-Jun Park 2 , Jordan E Gardiner 1 , Emily C Webb 1 , Adam C Sedgwick 3 , Juyoung Yoon 4 , Steven D Bull 1 , Hwan Myung Kim 2 , Tony D James 1
Affiliation  

In this work, we have developed an ESIPT-based benzimidazole platform (MO-E1 and MO-E2) for the two-photon cell imaging of ONOO and a potential ONOO-activated theranostic scaffold (MO-E3). Each benzimidazole platform, MO-E1–3, were shown to rapidly detect ONOO at micromolar concentrations (LoD = 0.28 μM, 6.53 μM and 0.81 μM respectively). The potential theranostic MO-E3 was shown to release the parent fluorophore and drug indomethacin in the presence of ONOO but unfortunately did not perform well in vitro due to low solubility. Despite this, the parent scaffold MO-E2 demonstrated its effectiveness as a two-photon imaging tool for the ratiometric detection of endogenous ONOO in RAW264.7 macrophages and rat hippocampus tissue. These results demonstrate the utility of this ESIPT benzimidazole-based platform for theranostic development and bioimaging applications.

中文翻译:

基于荧光 ESIPT 的苯并咪唑平台,用于 ONOO−体外和离体比率双光子成像

在这项工作中,我们开发了一种基于 ESIPT 的苯并咪唑平台(MO-E1MO-E2 ),用于ONOO−的双光子细胞成像,以及潜在的 ONOO−激活的治疗诊断支架(MO-E3)。每个苯并咪唑平台MO-E1–3均能快速检测微摩尔浓度的 ONOO -(LoD 分别为 0.28 μM、6.53 μM 和 0.81 μM)。潜在的治疗诊断MO-E3在 ONOO 存在的情况下会释放母体荧光团和药物吲哚美辛但不幸的是,由于溶解度低,在体外表现不佳。尽管如此,母体支架MO-E2证明了其作为双光子成像工具的有效性,可用于对 RAW264.7 巨噬细胞和大鼠海马组织中的内源性 ONOO 进行比例检测。这些结果证明了这种基于 ESIPT 苯并咪唑的平台在治疗诊断开发和生物成像应用中的实用性。
更新日期:2020-07-22
down
wechat
bug